Search Results

1.Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?.

Jihye PARK ; Jae Hee CHEON

Intestinal Research 2017;15(3):263-265

2.Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response?.

Joon Min JUNG ; Ye Jin LEE ; Chong Hyun WON ; Sung Eun CHANG ; Mi Woo LEE ; Jee Ho CHOI ; Kee Chan MOON

Annals of Dermatology 2015;27(5):620-621

3.Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response?.

Joon Min JUNG ; Ye Jin LEE ; Chong Hyun WON ; Sung Eun CHANG ; Mi Woo LEE ; Jee Ho CHOI ; Kee Chan MOON

Annals of Dermatology 2015;27(5):620-621

4.A Case of SAPHO Presented with Venous Engorgement: Successful Treatment with Adalimumab.

Seongcheol CHO ; Eun Bong LEE ; Hyo Cheol KIM

Journal of Rheumatic Diseases 2016;23(1):76-77

5.Comparative Efficacy and Safety of Secukinumab and Adalimumab in Patients with Active Ankylosing Spondylitis: A Bayesian Network Meta-analysis of Randomized Controlled Trials.

Young Ho LEE ; Gwan Gyu SONG

Journal of Rheumatic Diseases 2017;24(4):211-219

OBJECTIVE: This study assessed the efficacy and safety of secukinumab and adalimumab in patients with active ankylosing spondylitis (AS). METHODS: A Bayesian network meta-analysis was performed with direct and indirect data collected from randomized controlled trials (RCTs) of efficacy and safety of secukinumab 75 mg, 150 mg and adalimumab 40 mg in patients with active AS. RESULTS: Five RCTs (1,483 patients) met the inclusion criteria. The Assessment in Spondyloarthritis International Society response criteria of ≥20% (ASAS20) response rate was significantly higher in the adalimumab 40 mg (Odds ratio [OR], 4.26; 95% credible interval [CrI], 2.09~8.08), secukinumab 150 mg (OR, 3.35; 95% CrI, 1.73~6.56), and 75 mg dose (OR, 2.44; 95% CrI, 1.06~5.05) than with placebo. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that adalimumab 40 mg had the highest probability of being the best treatment for achieving an ASAS20 response (SUCRA=0.8753), followed by secukinumab 150 mg (SUCRA=0.7051), secukinumab 75 mg (SUCRA=0.4113), and placebo (SUCRA=0.0083). The ASAS40 response rate distribution pattern was similar to the ASAS20 response rate. However, the number of serious adverse events did not differ significantly among the treatment options. CONCLUSION: Secukinumab and adalimumab were effective for the treatment of active AS without causing a significant risk of serious adverse events.
Adalimumab* ; Humans ; Spondylitis, Ankylosing*

6.Reversible Corpus Callosal Lesions Associated with the Use of Adalimumab for Ulcerative Colitis.

Jin Woo PARK ; Hung Yuol SEOK ; Yoohwan KIM ; Byung Jo KIM

Journal of Clinical Neurology 2017;13(2):209-211

7.New-onset Psoriasis Induced by Adalimumab Administered for Rheumatoid Arthritis.

Hyun Yi SUH ; Kyung Ho KIM ; Ji Young AHN ; Mi Youn PARK ; Jai Il YOUN

Korean Journal of Dermatology 2017;55(7):480-482

8.Influence of Trough Serum Levels and Immunogenicity onLong-term Outcome of Adalimumab Therapy in Crohn's Disease(Gastroenterology 2009;137:1628-1640).

Geom Seog SEO

Intestinal Research 2009;7(2):135-136

9.Influence of Trough Serum Levels and Immunogenicity onLong-term Outcome of Adalimumab Therapy in Crohn's Disease(Gastroenterology 2009;137:1628-1640).

Geom Seog SEO

Intestinal Research 2009;7(2):135-136

10.Tuberculosis Cutis Orificialis in Adalimumab Related Immunosupressive Patient.

Mehdi ISKANDARLI ; Bengu GERCEKER TURK ; Banu YAMAN ; Naim CEYLAN ; Can CEYLAN

Annals of Dermatology 2017;29(1):114-116